# A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients

> **NCT00391196** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 975 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Placebo
- **DRUG:** CP-945,598
- **DRUG:** CP-945,598 Treatment B

## Key facts

- **NCT ID:** NCT00391196
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2008-12
- **Final completion:** 2009-01
- **Target enrollment:** 975 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391196, "A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00391196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*